Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068029 | 0.84 | ELANE (0.49) | ELANETRPA1CTSKCTSS | |
| SCHEMBL7007704 | 0.77 | ELANE (0.55) | ELANE | |
| Hydrochloric Acid SCHEMBL7075284 | 0.76 | ELANE (0.48) | ELANEMAPT | |
| SCHEMBL7199762 | 0.75 | ELANE (0.71) | ELANE | |
| SCHEMBL7438422 | 0.74 | TRPA1 (0.57) | TRPA1CTSKCTSSATMCTSL | |
| SCHEMBL8283003 | 0.74 | TRPA1 (0.57) | TRPA1CTSKCTSSATMCTSL | |
| SCHEMBL7956686 | 0.74 | ELANE (0.48) | ELANEMAPT | |
| SCHEMBL7158995 | 0.73 | ELANE (0.89) | ELANE | |
| SCHEMBL27158525 | 0.73 | PTPN1 (0.46) | ELANEMAPT | |
| SCHEMBL30522758 | 0.71 | TRPA1 (0.46) | TRPA1CTSKCTSSMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO., LTD. | 2003-08-14 | — | — | US | claimed |
| US-6534658-B1 | Intermediates for producing pharmaceuticals | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | claimed |
| EP-1162199-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | claimed |
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO., LTD. | 2003-08-14 | — | — | US | disclosed |
| US-6534658-B1 | Intermediates for producing pharmaceuticals | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-1162199-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | OXA1L, CYP1B1, OXER1 | ELANE 4189/4885TRPA1 2697/4885CTSK 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.